0.15Open0.18Pre Close48 Volume4.62K Open Interest2.50Strike Price923.00Turnover65.52%IV8.10%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.17Extrinsic Value100Contract SizeAmericanOptions Type0.5174Delta0.8831Gamma14.53Leverage Ratio-0.0033Theta0.0009Rho7.52Eff Leverage0.0027Vega
Esperion Therapeutics Stock Discussion
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion (ESPR) presented new exploratory data from the CLEAR Outcomes trial at the 2024 AHA Scientific Sessions, highlighting significant benefits of NEXLETOL (bempedoic acid).
The analysis showed patients with Peripheral Artery Disease (PAD) tak...
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $Viking Therapeutics (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esper...
No comment yet